We are live on ! Find out more
ACM

Aquilo Capital Management Portfolio holdings

AUM $55.8M
1-Year Est. Return 41.76%
This Fund
S&P 500
This Quarter Est. Return
+8.21%
1 Year Est. Return
-41.76%
3 Year Est. Return
-6.84%
5 Year Est. Return
+20.73%
10 Year Est. Return
–
AUM
$239M
AUM Growth
+$118M
Cap. Flow
+$59M
Cap. Flow %
24.69%
Top 10 Hldgs %
98.42%
Holding
15
New
1
Increased
7
Reduced
3
Closed
3

Top Buys

Rank Stock Value
1
SYBX
Synlogic
SYBX
+$7.31M
2
XENE icon
Xenon Pharmaceuticals
XENE
+$6.87M
3
FATE icon
Fate Therapeutics
FATE
+$4.78M
4
SPRO icon
Spero Therapeutics
SPRO
+$4.44M
5
MRUS
Merus
MRUS
+$951K

Top Sells

Rank Stock Value
1
AUTL
Autolus Therapeutics
AUTL
+$4.02M
2
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$3.67M
3
CLLS
Cellectis
CLLS
+$3.36M
4
LOXO
Loxo Oncology, Inc
LOXO
+$2.94M
5
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$1.02M

Sector Composition

Rank Sector Weight
1 Healthcare 55.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.3B
$105M 44.14%
1,100,000
+500,000
+83% +$48.5M
MRUS
2
DELISTED
Merus
MRUS
$25.6M 10.7%
1,295,713
+44,799
+4% +$951K
LOXO
3
DELISTED
Loxo Oncology, Inc
LOXO
$18.7M 7.82%
109,312
-17,500
-14% -$2.94M
FATE icon
4
Fate Therapeutics
FATE
$326M
$16M 6.71%
984,596
+404,367
+70% +$4.78M
KDNY
5
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$15.5M 6.48%
421,056
+19,476
+5% +$625K
SYBX
6
DELISTED
Synlogic
SYBX
$14.2M 5.94%
66,536
+46,083
+225% +$7.31M
CTMX icon
7
CytomX Therapeutics
CTMX
$754M
$12.5M 5.22%
674,763
+25,000
+4% +$570K
PVLA
8
Palvella Therapeutics
PVLA
$2.27B
$11.1M 4.63%
24,689
– –
SPRO icon
9
Spero Therapeutics
SPRO
$73M
$8.4M 3.52%
799,691
+383,000
+92% +$4.44M
XENE icon
10
Xenon Pharmaceuticals
XENE
$6.12B
$7.83M 3.27%
+592,802
New +$6.87M
LKFT
11
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.77B
$3.52M 1.47%
31,320
-34,730
-53% -$3.67M
MOR
12
DELISTED
MorphoSys AG American Depositary Shares
MOR
$243K 0.1%
9,087
-913
-9% -$27.4K
AUTL
13
Autolus Therapeutics
AUTL
$562M
– –
-150,000
Closed -$4.02M
CLLS
14
Cellectis
CLLS
$285M
– –
-118,873
Closed -$3.36M
FPRX
15
DELISTED
Five Prime Therapeutics, Inc.
FPRX
– –
-64,881
Closed -$1.02M

Similar funds

VCM
VeriStar Capital Management New York $54.7M AUM 2.08% 1-Year Est. Return
YEPV
Yorktown Energy Partners VIII New York $52.9M AUM 30% 1-Year Est. Return
HWP
Heritage Wealth Partners Dublin, Ohio $65.6M AUM 16.69% 1-Year Est. Return
GIS
Grayhawk Investment Strategies Calgary, Alberta, Canada $43.9M AUM 6.23% 1-Year Est. Return
AA
AlphaQ Advisors Winter Park, Florida $41.7M AUM 12.96% 1-Year Est. Return
PGIM
Pacific Global Investment Management Glendale, California $70.7M AUM 14.46% 1-Year Est. Return
RGMC
Revolution Growth Management Company Washington, District of Columbia $70.8M AUM 20.1% 1-Year Est. Return
PAM
Pamalican Asset Management Hong Kong $75.4M AUM

Aquilo Capital Management's Q3 2018 Portfolio in Review

As of Q3 2018, Aquilo Capital Management held 15 positions worth $239M, up 97% from $121M the previous quarter. Its ten largest holdings account for 98% of the portfolio.

Aquilo Capital Management deployed $59M of net new capital in Q3 2018, opening 1 new position and adding to 7 existing holdings. Its largest new stake was Xenon Pharmaceuticals: 592,802 shares worth $7.83M.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, down from 99% a quarter earlier.

On the sell side, the largest reduction was Lakefront Biotherapeutics American Depositary Shares, an estimated $3.67M trimmed.

  • Aquilo Capital Management's largest Q3 2018 buy was Xenon Pharmaceuticals: 592,802 shares worth $7.83M.
  • Aquilo Capital Management added most to Synlogic in Q3 2018, an estimated $7.31M increase.
  • Aquilo Capital Management's biggest Q3 2018 reduction was Lakefront Biotherapeutics American Depositary Shares, cutting an estimated $3.67M.
  • Aquilo Capital Management fully exited Autolus Therapeutics in Q3 2018, selling an estimated $4.02M.
  • Aquilo Capital Management's ten largest holdings make up 98% of its $239M portfolio in Q3 2018.
  • Aquilo Capital Management opened 1 new position and closed 3 in Q3 2018.
  • Aquilo Capital Management's portfolio value rose 97% quarter-over-quarter to $239M.

Based on Aquilo Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.